Ovid Therapeutics (OVID) Change in Acquisitions & Divestments (2018 - 2026)

Ovid Therapeutics (OVID) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $10.0 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments changed 0.0% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.0 million (down 61.11% YoY) and the FY2025 annual result came in at $42.0 million, down 67.19% from the prior year.
• Change in Acquisitions & Divestments advanced to $10.0 million in Q1 2026, from $5.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $60.0 million in Q4 2022 to a low of $5.0 million in Q4 2025.
• A 5-year average of $26.0 million and a median of $25.0 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2024 — Change in Acquisitions & Divestments surged 280.0% — and 2025, when it plunged 86.84%.
• Tracing OVID's Change in Acquisitions & Divestments over 5 years: stood at $60.0 million in 2022, then plunged by 83.33% to $10.0 million in 2023, then surged by 280.0% to $38.0 million in 2024, then sank by 86.84% to $5.0 million in 2025, then surged by 100.0% to $10.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $10.0 million (Q1 2026), $5.0 million (Q4 2025), and $10.0 million (Q3 2025), per Business Quant data.